Results 171 to 180 of about 27,905 (224)
Some of the next articles are maybe not open access.
Post-translational processing of beta-secretase in Alzheimer's disease
Proteomics, 2005AbstractBeta‐amyloid is released into the brains of Alzheimer's patients, where it aggregates and causes damage to neurons. It is cleaved proteolytically from a large transmembrane glycoprotein amyloid precursor protein by a membrane‐bound protease, known as beta‐secretase identified previously as the acid protease, Asp‐2. We have shown previously that
Brian Austen
exaly +3 more sources
Lipids, beta-secretase 1, and Alzheimer disease
2021An imbalance in lipid metabolism in Alzheimer disease (AD) is still poorly understood. Phospholipids (PLs) have multifactorial participation in AD, including the hyperactivation of phospholipases, mitochondrial stress, peroxisomal dysfunction, and irregular fatty acid composition.
Villamil-Ortiz, J. +2 more
openaire +2 more sources
Memapsin 2 (Beta-Secretase) Inhibitors: Drug Development
Current Alzheimer Research, 2008Memapsin 2 (beta-secretase, BACE 1) processing of beta-amyloid precursor protein is the first step in the pathway leading to the production of amyloid-beta, thus, it is a major target for the development of inhibitor drug for the treatment of Alzheimers's Disease.
Arun K, Ghosh +4 more
openaire +2 more sources
Splice variants of the Alzheimer’s disease beta-secretase, BACE1
neurogenetics, 2012Cleavage of the amyloid precursor protein by enzymes commonly referred to as β- and γ-secretase constitute an important process in the pathogenesis of Alzheimer's disease (AD). The regulation of this process is therefore an important subject of investigation.
Holsinger, RMD +3 more
openaire +3 more sources
Amyloid‐beta reduction by memapsin 2 (beta‐secretase) immunization
The FASEB Journal, 2007ABSTRACT Memapsin 2 (β‐secretase, BACE1) is the protease that initiates cleavage of β‐amyloid precursor protein leading to the production of amyloid‐β (Aβ) and the onset of Alzheimer's disease (AD). Reducing Aβ by targeting memapsin 2 is a major strategy in developing new AD therapy.
Wan-Pin, Chang +5 more
openaire +2 more sources
Memapsin 2 (Beta-Secretase) Inhibitor Drug, between Fantasy and Reality
Current Alzheimer Research, 2007A major strategy for the development of a disease-modifying therapy against Alzheimer's disease is pharmacological intervention designed to reduce levels of beta-amyloid in the brain. Among various ways of reducing beta-amyloid production, the inhibition of beta-secretase (memapsin 2, BACE) is particularly attractive.
Arun K, Ghosh +4 more
openaire +2 more sources